GSH activity was evaluated in vitro using an oxygen and glucose deprivation (OGD) model of adipose-derived stem cells

You should contact your GP if: Cravings are intense and persistent , significantly interfering with your daily life or causing distress You find yourself binge eating or losing control around sugary foods, which may indicate an underlying eating disorder requiring specialist support (your GP can refer you to appropriate services, or you can contact Beat, the UK eating disorders charity) Cravings are accompanied by other symptoms such as shakiness, sweating, confusion, or palpitations, which could suggest hypoglycaemia (low blood sugar), particularly if you have diabetes You're not losing weight as expected despite adhering to Wegovy treatment, as this may indicate that cravings are leading to excessive calorie intake that counteracts the medication's effects You experience mood changes such as depression, anxiety, or irritability alongside cravings, as these may require separate assessment and management You have a history of eating disorders , as Wegovy treatment may require additional psychological support in such cases Seek urgent medical attention if you experience: Severe, persistent upper abdominal pain with or without vomiting, which could indicate pancreatitis or gallbladder disease (known risks with semaglutide) [1] [2] Persistent vomiting leading to inability to keep fluids down, which may cause dehydration Your GP can assess whether your cravings might be related to factors such as inadequate nutrition, blood sugar imbalances, medication interactions, or psychological issues

The trade-off is that you have room to titrate upward, whereas Wegovy tops out at 2.4 mg

Phase 1: Weeks 13 (Disc Repair Priority) BPC-157: 500mcg/day subQ TB-500: 2.5mg/week subQ GHK-Cu: 1mg/day subQ Focus: disc tissue repair, nerve decompression, anti-inflammation Activity: physical therapy, gentle mobility, no loading Phase 2: Weeks 48 (Add Recomp Layer) Continue Phase 1 stack Add CJC-1295 no DAC + Ipamorelin: 100mcg each, pre-bed This layer drives GH pulsatility for tissue remodeling and begins the body recomposition phase Activity: begin light lifting as cleared by PT Phase 3: Weeks 9+ (Maintenance and Fat Loss) TB-500: Drop to maintenance 1.25mg/week BPC-157: Can drop to 250mcg/day or 5 days/week CJC+Ipa: Continue pre-bed Optional add: Tesamorelin (12mg/day, 5 days/week) for visceral fat and GH optimization pairs well with CJC+Ipa Optional add: Retatrutide for more aggressive fat loss if that's a priority What to Expect: Recovery Timeline Weeks 12: Reduced acute nerve pain is often the first noticeable change

Microdosing GLP-1 drugs is gaining popularity among people seeking to lose weight